Join Growin Stock Community!

Caredx, incCDNA.US Overview

US StockHealthcare
(No presentation for CDNA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CDNA AI Insights

CDNA Overall Performance

CDNA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CDNA Recent Performance

0.91%

Caredx, inc

0.05%

Avg of Sector

-0.31%

S&P500

CDNA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CDNA Key Information

CDNA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CDNA Profile

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Price of CDNA

CDNA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CDNA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.42
PE Ratio (TTM)
14.66
Forward PE
-
PS Ratio (TTM)
2.63
PB Ratio
3.11
Price-to-FCF
26.96
METRIC
VALUE
vs. INDUSTRY
Gross Margin
67.55%
Net Margin
-5.62%
Revenue Growth (YoY)
13.79%
Profit Growth (YoY)
14.46%
3-Year Revenue Growth
9.57%
3-Year Profit Growth
11.27%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.42
PE Ratio (TTM)
14.66
Forward PE
-
PS Ratio (TTM)
2.63
PB Ratio
3.11
Price-to-FCF
26.96
Gross Margin
67.55%
Net Margin
-5.62%
Revenue Growth (YoY)
13.79%
Profit Growth (YoY)
14.46%
3-Year Revenue Growth
9.57%
3-Year Profit Growth
11.27%

  • When is CDNA's latest earnings report released?

    The most recent financial report for Caredx, inc (CDNA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CDNA's short-term business performance and financial health. For the latest updates on CDNA's earnings releases, visit this page regularly.

  • Where does CDNA fall in the P/E River chart?

    According to historical valuation range analysis, Caredx, inc (CDNA)'s current price-to-earnings (P/E) ratio is -44.28, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of CDNA?

    According to the latest financial report, Caredx, inc (CDNA) reported an Operating Profit of -6.04M with an Operating Margin of -5.57% this period, representing a decline of 108.09% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CDNA's revenue growth?

    In the latest financial report, Caredx, inc (CDNA) announced revenue of 108.39M, with a Year-Over-Year growth rate of 25.19%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does CDNA have?

    At the end of the period, Caredx, inc (CDNA) held Total Cash and Cash Equivalents of 65.98M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CDNA go with three margins increasing?

    In the latest report, Caredx, inc (CDNA) did not achieve the “three margins increasing” benchmark, with a gross margin of 67.2%%, operating margin of -5.57%%, and net margin of -3.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CDNA's profit trajectory and future growth potential.

  • Is CDNA's EPS continuing to grow?

    According to the past four quarterly reports, Caredx, inc (CDNA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CDNA?

    Caredx, inc (CDNA)'s Free Cash Flow (FCF) for the period is 19.39M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 4.79% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CDNA?

    The latest valuation data shows Caredx, inc (CDNA) has a Price-To-Earnings (PE) ratio of -44.28 and a Price/Earnings-To-Growth (PEG) ratio of 0.17. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.